Cysteine cathepsins as regulators of the cytotoxicity of nk and t cells

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Nanut, Milica Perišić ^a   Sabotič, Jerica ^a   Jewett, Anahid ^b   Kos, Janko ^a,c  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b UCLA SCHOOL OF DENTISTRY   (United States)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cathepsins; Cystatins; Cytotoxic T cells; Cytotoxicity; Natural killer cells

Indexed keywords

ALPHA ACTININ 1; CATHEPSIN H; CATHEPSIN L; CATHEPSIN V; CATHEPSIN W; CATHEPSIN X; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYSTATIN; CYSTATIN C; DIPEPTIDYL PEPTIDASE I; FAS ANTIGEN; GRANZYME A; GRANZYME B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN; REGULATOR PROTEIN; TALIN;

CD8+ T LYMPHOCYTE; CELL ADHESION; CELL DEATH; CELL MATURATION; CELL MIGRATION; CELL PHAGOCYTOSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNE RESPONSE; NATURAL KILLER CELL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; UPREGULATION;

EID: 84919710675     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00616     Document Type: Review

References (144)

1. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res (2012) 40:D343-50. doi: 10.1093/nar/gkr987
2. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov (2006) 5:785-99. doi:10.1038/nrd2092
3. Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta (2012) 1824:68-88. doi:10.1016/j.bbapap.2011.10.002
4. Kopitar-Jerala N. The role of cysteine proteinases and their inhibitors in the host-pathogen cross talk. Curr Protein Pept Sci (2012) 13:767-75. doi:10.2174/138920312804871102
5. Obermajer N, Doljak B, Kos J. Cysteine cathepsins: regulators of antitumour immune response. Expert Opin Biol Ther (2006) 6:1295-309. doi:10.1517/14712598.6.12.1295
6. Bird PI, Trapani JA, Villadangos JA. Endolysosomal proteases and their inhibitors in immunity. Nat Rev Immunol (2009) 9:871-82. doi:10.1038/nri2671
7. Shi GP, Bryant RA, Riese R, Verhelst S, Driessen C, Li Z, et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med (2000) 191:1177-86. doi:10.1084/jem.191.7.1177
8. Kos J, Jevnikar Z, Obermajer N. The role of cathepsin X in cell signaling. Cell Adh Migr (2009) 3:164-6. doi:10.4161/cam.3.2.7403
9. Hafner A, Glavan G, Obermajer N, Zivin M, Schliebs R, Kos J. Neuroprotective role of gamma-enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X. Aging Cell (2013) 12:604-14. doi:10.1111/acel.12093
10. Roberts R. Lysosomal cysteine proteases: structure, function and inhibition of cathepsins. Drug News Perspect (2005) 18:605-14. doi:10.1358/dnp.2005.18.10.949485
11. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J (2001) 20:4629-33. doi:10.1093/emboj/20.17.4629
12. Turk D, Guncar G, Podobnik M, Turk B. Revised definition of substrate binding sites of papain-like cysteine proteases. Biol Chem (1998) 379:137-47. doi:10.1515/bchm.1998.379.2.137
13. Turk D, Guncar G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr (2003) 59:203-13. doi:10.1107/S0907444902021479
14. Musil D, Zucic D, Turk D, Engh RA I, Mayr R, Huber T, et al. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J (1991) 10:2321-30.
15. Therrien C, Lachance P, Sulea T, Purisima EO, Qi H, Ziomek E, et al. Cathepsins X and B can be differentiated through their respective mono- and dipeptidyl carboxypeptidase activities. Biochemistry (2001) 40:2702-11. doi:10.1021/bi002460a
16. Guncar G, Podobnik M, Pungercar J, Strukelj B, Turk V, Turk D. Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function. Structure (1998) 6:51-61. doi:10.1016/S0969-2126(98)00007-0
17. Barrett AJ, Kirschke H. Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol (1981) 80(Pt C):535-61.
18. Vasiljeva O, Dolinar M, Turk V, Turk B. Recombinant human cathepsin H lacking the mini chain is an endopeptidase. Biochemistry (2003) 42:13522-8. doi:10.1021/bi035355k
19. Karrer KM, Peiffer SL, DiTomas ME. Two distinct gene subfamilies within the family of cysteine protease genes. Proc Natl Acad Sci U S A (1993) 90:3063-7. doi:10.1073/pnas.90.7.3063
20. Novinec M, Lenarcic B. Cathepsin K: a unique collagenolytic cysteine peptidase. Biol Chem (2013) 394:1163-79. doi:10.1515/hsz-2013-0134
21. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases) - on the main stage of cancer? Cancer Cell (2004) 5:409-10. doi:10.1016/S1535-6108(04)00117-5
22. Dubin G. Proteinaceous cysteine protease inhibitors. Cell Mol Life Sci (2005) 62:653-69. doi:10.1007/s00018-004-4445-9
23. Keppler D. Towards novel anti-cancer strategies based on cystatin function. Cancer Lett (2006) 235:159-76. doi:10.1016/j.canlet.2005.04.001
24. Abrahamson M, Barrett AJ, Salvesen G, Grubb A. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem (1986) 261:11282-9.
25. Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins. Biochem Soc Symp (2003) 70:179-99.
26. Bode W, Engh R, Musil D, Thiele U, Huber R, Karshikov A, et al. The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J (1988) 7:2593-9.
27. Alvarez-Fernandez M, Barrett AJ, Gerhartz B, Dando PM, Ni J, Abrahamson M. Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J Biol Chem (1999) 274:19195-203. doi:10.1074/jbc.274.27.19195
28. Colbert JD, Matthews SP, Kos J, Watts C. Internalization of exogenous cystatin F supresses cysteine proteases and induces the accumulation of single-chain cathepsin L by multiple mechanisms. J Biol Chem (2011) 286:42082-90. doi:10.1074/jbc. M111.253914
29. Wallin H, Abrahamson M, Ekstrom U. Cystatin C properties crucial for uptake and inhibition of intracellular target enzymes. J Biol Chem (2013) 288:17019-29. doi:10.1074/jbc. M113.453449
30. Hanada K, Tamai M, Yamagishi M, Ohmura S, Sawada J, Tanaka I. Isolation and characterization of E 64, a new thiol protease inhibitor. Agric Biol Chem (1978) 42:523-8. doi:10.1271/bbb1961.42.523
31. Murata M, Miyashita S, Yokoo C, Tamai M, Hanada K, Hatayama K, et al. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett (1991) 280:307-10. doi:10.1016/0014-5793(91)80318-W
32. Kos FJ, Mitrovic A, Mirkovic B. The current stage of cathepsin B inhibitors as potential anti-cancer agents. Future Med Chem (2014) 6:1335-71. doi:10.4155/fmc.14.73
33. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol (2002) 20:323-70. doi:10.1146/annurev.immunol.20.100201.131730
34. Mullbacher A, Waring P, Tha Hla R, Tran T, Chin S, Stehle T, et al. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci U S A (1999) 96:13950-5. doi:10.1073/pnas.96.24.13950
35. van Dommelen SL, Sumaria RD, Fau-Schreiber N, Schreiber AA, Fau-Scalzo RD, Scalzo MJ, et al. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity (2006) 25:835-48.
36. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol (2002) 2:735-47. doi:10.1038/nri911
37. Hayakawa Y, Kelly JM, Westwood JA, Darcy PK, Diefenbach A, Raulet D, et al. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol (2002) 169:5377-81. doi:10.4049/jimmunol.169.10.5377
38. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest (1997) 100:904-11. doi:10.1172/JCI119606
39. Burkhardt JK, Hester S, Lapham CK, Argon Y. The lytic granules of natural killer cells are dual-function organelles combining secretory and pre-lysosomal compartments. J Cell Biol (1990) 111:2327-40. doi:10.1083/jcb.111.6.2327
40. Peters PJ, Borst J, Oorschot V, Fukuda M, Krahenbuhl O, Tschopp J, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med (1991) 173:1099-109. doi:10.1084/jem.173.5.1099
41. Blott EJ, Griffiths GM. Secretory lysosomes. Nat Rev Mol Cell Biol (2002) 3:122-31. doi:10.1038/nrm732
42. D'Angelo ME, Bird PI, Peters C, Reinheckel T, Trapani JA, Sutton VR. Cathepsin H is an additional convertase of pro-granzyme B. J Biol Chem (2010) 285:20514-9. doi:10.1074/jbc. M109.094573
43. Shinkai Y, Takio K, Okumura K. Homology of perforin to the ninth component of complement (C9). Nature (1988) 334:525-7. doi:10.1038/334525a0
44. Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol (2006) 6:940-52. doi:10.1038/nri1983
45. Uellner R, Zvelebil J, Fau-Hopkins MJ, Hopkins J, Fau-Jones J, Jones LK, et al. Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J (1997) 16:7287-96.
46. Kagi D, Ledermann K, Fau-Burki B, Burki P, Fau-Seiler K, Seiler B, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 369:31-7.
47. Mouchacca P, Schmitt-Verhulst AM, Boyer C. Visualization of cytolytic T cell differentiation and granule exocytosis with T cells from mice expressing active fluorescent granzyme B. PLoS One (2013) 8:e67239. doi:10.1371/journal.pone.0067239
48. van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 184:1781-90. doi:10.1084/jem.184.5.1781
49. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science (1999) 286:1957-9. doi:10.1126/science.286.5446.1957
50. Jenne DE, Tschopp J. Granzymes, a family of serine proteases released from granules of cytolytic T lymphocytes upon T cell receptor stimulation. Immunol Rev (1988) 103:53-71. doi:10.1111/j.1600-065X.1988.tb00749.x
51. Jenne DE, Masson D, Zimmer M, Haefliger JA, Li WH, Tschopp J. Isolation and complete structure of the lymphocyte serine protease granzyme G, a novel member of the granzyme multigene family in murine cytolytic T lymphocytes. Evolutionary origin of lymphocyte proteases. Biochemistry (1989) 28:7953-61.
52. Sedelies KA, Sayers TJ, Edwards KM, Chen W, Pellicci DG, Godfrey DI, et al. Discordant regulation of granzyme H and granzyme B expression in human lymphocytes. J Biol Chem (2004) 279:26581-7. doi:10.1074/jbc. M312481200
53. Bade B, Boettcher HE, Lohrmann J, Hink-Schauer C, Bratke K, Jenne DE, et al. Differential expression of the granzymes A, K and M and perforin in human peripheral blood lymphocytes. Int Immunol (2005) 17:1419-28. doi:10.1093/intimm/dxh320
54. Bratke K, Kuepper M, Bade B, Virchow JC Jr, Luttmann W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur J Immunol (2005) 35:2608-16. doi:10.1002/eji.200526122
55. Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol (2008) 26:389-420. doi:10.1146/annurev.immunol.26.021607.090404
56. Sayers TJ, Brooks AD, Ward JM, Hoshino T, Bere WE, Wiegand GW, et al. The restricted expression of granzyme M in human lymphocytes. J Immunol (2001) 166:765-71. doi:10.4049/jimmunol.166.2.765
57. Caputo A, Garner RS, Winkler U, Hudig D, Bleackley RC. Activation of recombinant murine cytotoxic cell proteinase-1 requires deletion of an amino-terminal dipeptide. J Biol Chem (1993) 268:17672-5.
58. Trapani JA, Sutton VR. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol (2003) 15:533-43. doi:10.1016/S0952-7915(03)00107-9
59. Thomas DA, Du C, Xu M, Wang X, Ley TJ. DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity (2000) 12:621-32. doi:10.1016/S1074-7613(00)80213-7
60. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell (2003) 112:659-72. doi:10.1016/S0092-8674(03)00150-8
61. Ebnet K, Hausmann M, Lehmann-Grube F, Mullbacher A, Kopf M, Lamers M, et al. Granzyme A-deficient mice retain potent cell-mediated cytotoxicity. EMBO J (1995) 14:4230-9.
62. Simon MM, Hausmann M, Tran T, Ebnet K, Tschopp J, ThaHla R, et al. In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A x B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J Exp Med (1997) 186:1781-6. doi:10.1084/jem.186.10.1781
63. Waterhouse NJ, Sutton KA, Fau-Sedelies VR, Sedelies A, Fau-Ciccone KA, Ciccone M, et al. Cytotoxic T lymphocyte-induced killing in the absence of granzymes A and B is unique and distinct from both apoptosis and perforin-dependent lysis. J Cell Biol (2006) 173:133-44.
64. Pardo J, Bosque A, Brehm R, Wallich R, Naval J, Mullbacher A, et al. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. J Cell Biol (2004) 167:457-68. doi:10.1083/jcb.200406115
65. Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, Freudenberg M, et al. Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity (2008) 29:720-33. doi:10.1016/j.immuni.2008.08.014
66. Buzza MS, Zamurs L, Sun J, Bird CH, Smith AI, Trapani JA, et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem (2005) 280:23549-58. doi:10.1074/jbc. M412001200
67. Devadas S, Das J, Liu C, Zhang L, Roberts AI, Pan Z, et al. Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity (2006) 25:237-47. doi:10.1016/j.immuni.2006.06.011
68. Andrade F, Casciola-Rosen LA, Rosen A. A novel domain in adenovirus L4-100K is required for stable binding and efficient inhibition of human granzyme B: possible interaction with a species-specific exosite. Mol Cell Biol (2003) 23:6315-26. doi:10.1128/MCB.23.17.6315-6326.2003
69. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol (2013) 31:163-94. doi:10.1146/annurev-immunol-032712-100001
70. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 2:850-61. doi:10.1038/nrc928
71. Sagiv A, Biran A, Yon M, Simon J, Lowe SW, Krizhanovsky V. Granule exocytosis mediates immune surveillance of senescent cells. Oncogene (2013) 32:1971-7. doi:10.1038/onc.2012.206
72. Caligiuri MA. Human natural killer cells. Blood (2008) 112:461-9. doi:10.1182/blood-2007-09-077438
73. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2011) 108:728-32. doi:10.1073/pnas.1012356108
74. Kos FJ, Engleman EG. Immune regulation: a critical link between NK cells and CTLs. Immunol Today (1996) 17:174-6. doi:10.1016/0167-5699(96)80616-5
75. Karre K. Natural killer cell recognition of missing self. Nat Immunol (2008) 9:477-80. doi:10.1038/ni0508-477
76. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 11:237-44. doi:10.1016/0167-5699(90)90097-S
77. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J (2004) 23:255-9. doi:10.1038/sj.emboj.7600019
78. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol (2008) 9:495-502. doi:10.1038/ni1581
79. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol (2013) 31:227-58. doi:10.1146/annurev-immunol-020711-075005
80. Krzewski K, Strominger JL. The killer's kiss: the many functions of NK cell immunological synapses. Curr Opin Cell Biol (2008) 20:597-605. doi:10.1016/j.ceb.2008.05.006
81. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev (2006) 214:56-72. doi:10.1111/j.1600-065X.2006.00451.x
82. Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood (2006) 108:3824-33. doi:10.1182/blood-2006-04-020198
83. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 106:2252-8. doi:10.1182/blood-2005-03-1154
84. Vankayalapati R, Klucar P, Wizel B, Weis SE, Samten B, SafiH, et al. NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen. J Immunol (2004) 172:130-7. doi:10.4049/jimmunol.172.1.130
85. Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, et al. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One (2010) 5:e11590. doi:10.1371/journal.pone.0011590
86. Jewett A, Man YG, Cacalano N, Kos J, Tseng HC. Natural killer cells as effectors of selection and differentiation of stem cells: role in resolution of inflammation. J Immunotoxicol (2014) 11:297-307. doi:10.3109/1547691X.2013.877104
87. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 103:5941-6. doi:10.1073/pnas.0601335103
88. Rabinovich BA, Li J, Shannon J, Hurren R, Chalupny J, Cosman D, et al. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells. J Immunol (2003) 170:3572-6. doi:10.4049/jimmunol.170.7.3572
89. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol (2008) 8:713-25. doi:10.1038/nri2381
90. Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol (2011) 187:781-90. doi:10.4049/jimmunol.1100789
91. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature (2009) 457:557-61. doi:10.1038/nature07665
92. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331:44-9. doi:10.1126/science.1198687
93. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood (2012) 119:2665-74. doi:10.1182/blood-2011-10-386995
94. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A (2011) 108:14725-32. doi:10.1073/pnas.1110900108
95. Abbey JL, O'Neill HC. Expression of T-cell receptor genes during early T-cell development. Immunol Cell Biol (2008) 86:166-74. doi:10.1038/sj.icb.7100120
96. Olsen I, Bou-Gharios G, Abraham D. The activation of resting lymphocytes is accompanied by the biogenesis of lysosomal organelles. Eur J Immunol (1990) 20:2161-70. doi:10.1002/eji.1830201003
97. Bou-Gharios G, Moss J, Olsen I, Partridge T. Ultrastructural localization of a lysosomal enzyme in resin-embedded lymphocytes. Histochemistry (1988) 89:69-74. doi:10.1007/BF00496587
98. Podack ER, Kupfer A. T-cell effector functions: mechanisms for delivery of cytotoxicity and help. Annu Rev Cell Biol (1991) 7:479-504. doi:10.1146/annurev.cellbio.7.1.479
99. Wang JH, Reinherz EL. Structural basis of T cell recognition of peptides bound to MHC molecules. Mol Immunol (2002) 38:1039-49. doi:10.1016/S0161-5890(02)00033-0
100. Bour-Jordan H, Blueston JA. CD28 function: a balance of costimulatory and regulatory signals. J Clin Immunol (2002) 22:1-7. doi:10.1023/A:1014256417651
101. Stinchcombe JC, Griffiths GM. Secretory mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol (2007) 23:495-517. doi:10.1146/annurev.cellbio.23.090506.123521
102. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol (1995) 25:1071-9. doi:10.1002/eji.1830250432
103. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 21:589-601. doi:10.1016/j.immuni.2004.09.002
104. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol (2005) 174:1783-6. doi:10.4049/jimmunol.174.4.1783
105. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood (2006) 107:3925-32. doi:10.1182/blood-2005-11-4502
106. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (2005) 307:1630-4. doi:10.1126/science.1108003
107. Rao NV, Rao GV, Hoidal JR. Human dipeptidyl-peptidase I. Gene characterization, localization, and expression. J Biol Chem (1997) 272:10260-5. doi:10.1074/jbc.272.15.10260
108. Wolters PJ, Raymond WW, Blount JL, Caughey GH. Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I. J Biol Chem (1998) 273:15514-20. doi:10.1074/jbc.273.25.15514
109. Zavasnik-Bergant V, Sekirnik A, Golouh R, Turk V, Kos J. Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue. Biol Chem (2001) 382:799-804.
110. Stoeckle C, Gouttefangeas C, Hammer M, Weber E, Melms A, Tolosa E. Cathepsin W expressed exclusively in CD8+ T cells and NK cells, is secreted during target cell killing but is not essential for cytotoxicity in human CTLs. Exp Hematol (2009) 37:266-75. doi:10.1016/j.exphem.2008.10.011
111. Beers C, Honey K, Fink S, Forbush K, Rudensky A. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages. J Exp Med (2003) 197:169-79. doi:10.1084/jem.20020978
112. Shi GP, Villadangos JA, DranoffG, Small C, Gu L, Haley KJ, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity (1999) 10:197-206. doi:10.1016/S1074-7613(00)80020-5
113. Kos J, Sekirnik A, Premzl A, Zavasnik-Bergant V, Langerholc T, Turk B, et al. Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues. Exp Cell Res (2005) 306:103-13. doi:10.1016/j.yexcr.2004.12.006
114. Pislar A, Kos J. Cysteine cathepsins in neurological disorders. Mol Neurobiol (2014) 49:1017-30. doi:10.1007/s12035-013-8576-6
115. Obermajer N, Premzl A, Zavasnik-Bergant T, Turk B, Kos J. Carboxypeptidase cathepsin X mediates beta2-integrin-dependent adhesion of differentiated U-937 cells. Exp Cell Res (2006) 312:2515-27. doi:10.1016/j.yexcr.2006.04.019
116. Obermajer N, SVajger U, Bogyo M, Jeras M, Kos J. Maturation of dendritic cells depends on proteolytic cleavage by cathepsin X. J Leukoc Biol (2008) 84:1306-15. doi:10.1189/jlb.0508285
117. Santamaria I, Velasco G, Pendas AM, Fueyo A, Lopez-Otin C. Cathepsin Z, a novel human cysteine proteinase with a short propeptide domain and a unique chromosomal location. J Biol Chem (1998) 273:16816-23. doi:10.1074/jbc.273.27.16816
118. Nagler DK, Menard R. Human cathepsin X: a novel cysteine protease of the papain family with a very short proregion and unique insertions. FEBS Lett (1998) 434:135-9. doi:10.1016/S0014-5793(98)00964-8
119. Lechner AM, Assfalg-Machleidt I, Zahler S, Stoeckelhuber M, Machleidt W, Jochum M, et al. RGD-dependent binding of procathepsin X to integrin alphavbeta3 mediates cell-adhesive properties. J Biol Chem (2006) 281:39588-97. doi:10.1074/jbc. M513439200
120. Jevnikar Z, Obermajer N, Doljak B, Turk S, Gobec S, Svajger U, et al. Cathepsin X cleavage of the beta2 integrin regulates talin-binding and LFA-1 affinity in T cells. J Leukoc Biol (2011) 90:99-109. doi:10.1189/jlb.1110622
121. Jevnikar Z, Obermajer N, Kos J. LFA-1 fine-tuning by cathepsin X. IUBMB Life (2011) 63:686-93. doi:10.1002/iub.505
122. Wendt W, Schulten R, Stichel CC, Lubbert H. Intra- versus extracellular effects of microglia-derived cysteine proteases in a conditioned medium transfer model. J Neurochem (2009) 110:1931-41. doi:10.1111/j.1471-4159.2009.06283.x
123. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci (2007) 8:57-69. doi:10.1038/nrn2038
124. Adkison AM, Raptis SZ, Kelley DG, Pham CT. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest (2002) 109:363-71. doi:10.1172/JCI13462
125. Pham CT, Ivanovich JL, Raptis SZ, Zehnbauer B, Ley TJ. Papillon-Lefevre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C/dipeptidyl peptidase I deficiency in humans. J Immunol (2004) 173:7277-81. doi:10.4049/jimmunol.173.12.7277
126. de Haar SF, Jansen DC, Schoenmaker T, De Vree H, Everts V, Beertsen W. Loss-of-function mutations in cathepsin C in two families with Papillon-Lefevre syndrome are associated with deficiency of serine proteinases in PMNs. Hum Mutat (2004) 23:524. doi:10.1002/humu.9243
127. Wolters PJ, Pham CT, Muilenburg DJ, Ley TJ, Caughey GH. Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice. J Biol Chem (2001) 276:18551-6. doi:10.1074/jbc. M100223200
128. Wex T, Buhling F, Wex H, Gunther D, Malfertheiner P, Weber E, et al. Human cathepsin W, a cysteine protease predominantly expressed in NK cells, is mainly localized in the endoplasmic reticulum. J Immunol (2001) 167:2172-8. doi:10.4049/jimmunol.167.4.2172
129. Balaji KN, Schaschke N, Machleidt W, Catalfamo M, Henkart PA. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med (2002) 196:493-503. doi:10.1084/jem.20011836
130. Baran K, Ciccone A, Peters C, Yagita H, Bird PI, Villadangos JA, et al. Cytotoxic T lymphocytes from cathepsin B-deficient mice survive normally in vitro and in vivo after encountering and killing target cells. J Biol Chem (2006) 281:30485-91. doi:10.1074/jbc. M602007200
131. Punturieri A, Filippov S, Allen E, Caras I, Murray R, Reddy V, et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J Exp Med (2000) 192:789-99. doi:10.1084/jem.192.6.789
132. Takayanagi H. The unexpected link between osteoclasts and the immune system. Adv Exp Med Biol (2010) 658:61-8. doi:10.1007/978-1-4419-1050-9_7
133. Konjar S, Sutton VR, Hoves S, Repnik U, Yagita H, Reinheckel T, et al. Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L. Immunology (2010) 131:257-67. doi:10.1111/j.1365-2567.2010.03299.x
134. Brown GR, McGuire MJ, Thiele DL. Dipeptidyl peptidase I is enriched in granules of in vitro- and in vivo-activated cytotoxic T lymphocytes. J Immunol (1993) 150:4733-42.
135. Sutton VR, Waterhouse NJ, Browne KA, Sedelies K, Ciccone A, Anthony D, et al. Residual active granzyme B in cathepsin C-null lymphocytes is sufficient for perforin-dependent target cell apoptosis. J Cell Biol (2007) 176:425-33. doi:10.1083/jcb.200609077
136. Soderstrom KO, Rinne R, Hopsu-Havu VK, Jarvinen M, Rinne A. Identification of acid cysteine proteinase inhibitor (cystatin A) in the human thymus. Anat Rec (1994) 240:115-9. doi:10.1002/ar.1092400111
137. Jarvinen M, Rinne A, Hopsu-Havu VK. Human cystatins in normal and diseased tissues - a review. Acta Histochem (1987) 82:5-18. doi:10.1016/S0065-1281(87)80043-0
138. Langerholc T, Zavasnik-Bergant V, Turk B, Turk V, Abrahamson M, Kos J. Inhibitory properties of cystatin F and its localization in U937 promonocyte cells. FEBS J (2005) 272:1535-45. doi:10.1111/j.1742-4658.2005.04594.x
139. Cappello F, Gatti E, Camossetto V, David A, Lelouard H, Pierre P. Cystatin F is secreted, but artificial modification of its C-terminus can induce its endocytic targeting. Exp Cell Res (2004) 297:607-18. doi:10.1016/j.yexcr.2004.03.048
140. Maher K, Konjar S, Watts C, Turk B, Kopitar-Jerala N. Cystatin F regulates proteinase activity in IL-2-activated natural killer cells. Protein Pept Lett (2014) 21:957-65. doi:10.2174/0929866521666140403124146
141. Hamilton G, Colbert JD, Schuettelkopf AW, Watts C. Cystatin F is a cathepsin C-directed protease inhibitor regulated by proteolysis. EMBO J (2008) 27:499-508. doi:10.1038/sj.emboj.7601979
142. Halfon S, Ford J, Foster J, Dowling L, Lucian L, Sterling M, et al. Leukocystatin, a new class II cystatin expressed selectively by hematopoietic cells. J Biol Chem (1998) 273:16400-8. doi:10.1074/jbc.273.26.16400
143. Ni J, Fernandez MA, Danielsson L, Chillakuru RA, Zhang J, Grubb A, et al. Cystatin F is a glycosylated human low molecular weight cysteine proteinase inhibitor. J Biol Chem (1998) 273:24797-804. doi:10.1074/jbc.273.38.24797
144. Magister S, Obermajer N, Mirkovic B, Svajger U, Renko M, Softic A, et al. Regulation of cathepsins S and L by cystatin F during maturation of dendritic cells. Eur J Cell Biol (2012) 91:391-401. doi:10.1016/j.ejcb.2012.01.001